Novartis Ofatumumab domestic launch time

Ofatumumab (Ofatumumab) will be approved by the National Medical Products Administration in 2021 for the treatment of relapse in adults. Multiple sclerosis (RMS), which includes clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS, in which patients have periods of mild or asymptomatic symptoms after onset (relapses), meaning they have signs of relapses and/or active inflammation on scans. This is a relatively rare disease. Ofatumumab is also included in the scope of Class B medical insurance, but it is only reimbursed for adults with relapsing multiple sclerosis (RMS). The trade name is Quanxinda, and the price is around tens of thousands of yuan.